The future of our field is indeed bright
The future of our field is indeed bright
Sounds like the 16 mos with early switch?
I know…. Cross trial comparisons are hard but lead time bias is real
Sounds like the 16 mos with early switch?
I know…. Cross trial comparisons are hard but lead time bias is real
PFS2 as defined is really PFS2 in control arm vs PFS3 in cami arm
Uninterpretable and real potential that pts will move to chemo sooner than needed
PFS2 as defined is really PFS2 in control arm vs PFS3 in cami arm
Uninterpretable and real potential that pts will move to chemo sooner than needed
The SMOG readability score
SMOG = simple measure of gobbledygook
Use it to determine the education level needed for comprehension
The SMOG readability score
SMOG = simple measure of gobbledygook
Use it to determine the education level needed for comprehension
Finally respect for pts who agree to participate
Finally respect for pts who agree to participate
How is endocrine therapy alone SOC for the 40 percent with no prior CDKi exposure?
When they amended to add illum plus abema arm they should have added SOC plus abema too
Without that control, the data are impossible to interpret
How is endocrine therapy alone SOC for the 40 percent with no prior CDKi exposure?
When they amended to add illum plus abema arm they should have added SOC plus abema too
Without that control, the data are impossible to interpret
If your attending stop by poster session 1 to learn about epigenetic therapy plus PARPis… just to say hello
If your attending stop by poster session 1 to learn about epigenetic therapy plus PARPis… just to say hello
www.youtube.com/watch?v=klOA...
www.youtube.com/watch?v=klOA...
www.youtube.com/watch?v=U2Iu...
www.youtube.com/watch?v=U2Iu...
www.youtube.com/watch?v=U2Iu...
www.youtube.com/watch?v=U2Iu...
sites.libsyn.com/115284/syste...
Recently published results of the phase III ADRIATIC trial (consolidation durva) and the phase II DeLLphi-301 (tarlatamab) prompted this important update
sites.libsyn.com/115284/syste...
Recently published results of the phase III ADRIATIC trial (consolidation durva) and the phase II DeLLphi-301 (tarlatamab) prompted this important update